Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study

Inclusion Criteria:

   - Patients who completed the LEROS study, who attended the end of study visit in LEROS
   and who in the opinion of investigator could benefit from continuation of idebenone
   treatment.

   - Signed and dated Informed Consent Form (to be obtained at the Enrollment Visit from
   patient or parent/legal guardian (if applicable) prior to dispensing idebenone to the
   patient).

Exclusion Criteria:

   - Patients who, in the opinion of the LEROS investigator, had unacceptable tolerability
   of idebenone treatment in LEROS trial.

   - Patients who prematurely discontinued the LEROS study.